is allulose a glp 1 agonist GLP-1-based therapies for type 2 diabetes: from single, dual and triple agonists to endogenous GLP-1 production and L-cell differentiation | Diabetology & Metabolic Syndrome d-Allulose improves glucose tolerance via

Brain uptake pharmacokinetics of albiglutide, dulaglutide, tirzepatide, and DA5-CH in the search for new treatments of Alzheimers and Parkinsons diseases

GLP-1-based treatments mark a major advancement in managing obesity and type 2 diabetes, offering added benefits for heart and brain health

After an average of 25 months, the primary composite outcome of CV death, myocardial infarction, stroke, or hospitalization for unstable angina occurred in 13.4% of individuals in the lixisenatide group compared to 13.2% in the placebo group (hazard ratio [HR] 1.02

Hypoglycemia: On their own, GLP-1 RAs have negligible hypoglycemia risk

Bioscience Rep